Stephen Welch

As Executive Vice President and Head of Specialty Generics, Stephen Welch leads Par Health, the company’s generics and sterile injectable business, which is intended to spin off as a standalone company in the months to come.

Mr. Welch previously served as the Senior Vice President and General Manager, Mallinckrodt Specialty Generics; the segment’s Chief Financial Officer; Chief Transformation Officer; Chief of Staff to the President and CEO; and Vice President of Corporate Strategy. Mr. Welch joined Mallinckrodt in 2012 in the tax department, focusing primarily on M&A transactions and business integrations.

Prior to joining Mallinckrodt, Mr. Welch led the tax functions at Human Genome Sciences, Inc., a formerly publicly listed biopharmaceutical company and PharMerica Corporation, a pharmacy services provider. He began his career at PricewaterhouseCoopers.

Mr. Welch holds a Juris Doctor from the Georgetown University Law Center and a Bachelor’s degree in Political Science from California State University, Bakersfield. In 2023, Mr. Welch completed Harvard Business School’s Advanced Management Program.